DAX
18.163,52 -90,68 (-0,50%) Euro Stoxx 50
4.907,30 -40,43 (-0,82%) Dow Jones 30
39.150,33 +15,53 (+0,04%) Gold
2.334,70 -34,30 (-1,45%) EUR/USD
1,0696 -0,0010 (-0,10%) Bitcoin EUR
59.974,52 -127,87 (-0,21%)
DURECT Corporation (DC8A.F)
DURECT Corporation
10240 Bubb Road
Cupertino, CA 95014-4166
United States
408 777 1417
https://www.durect.com
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 48
Beschreibung
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Corporate Governance
DURECT Corporations ISS Governance QualityScore, Stand 1. Juni 2024, lautet 6. Die grundlegenden Scores sind Audit: 9, Vorstand: 2, Shareholderrechte: 7, Kompensation: 5.
